|
| Wednesday, August 16, 2023 |
|
|
亿胜生物公布2023年中期业绩 收入同比增长37.1% 净利润同比增长22.0% |
| 亿胜生物科技有限公司（「亿胜生物」或「集团」；股份代码：1061.HK）今日公布截至2023年6月30日止（「回顾期内」）的中期财务业绩。 more info >> |
|
|
億勝生物公佈2023年中期業績 收入同比增長37.1% 淨利潤同比增長22.0% |
| 億勝生物科技有限公司（「億勝生物」或「集團」；股份代碼：1061.HK）今日公佈截至2023年6月30日止（「回顧期內」）的中期財務業績。 more info >> |
|
|
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22% |
Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").
more info >> |
|
| Wednesday, July 26, 2023 |
|
|
亿胜生物宣布贝伐珠单抗眼科适应症I/II期临床研究成功完成 |
| 亿胜生物科技有限公司（「亿胜生物」或「集团」，股票代码：1061.HK）今日宣布，集团与上海复宏汉霖生物技术股份有限公司（「复宏汉霖」，股票代码：2696.HK）合作开发的重组抗血管内皮生长因子(Vascular endothelial growth factor, VEGF) more info >> |
|
|
億勝生物宣布貝伐珠單抗眼科適應症I/II期臨床研究成功完成 |
| 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）今日宣布，集團與上海復宏漢霖生物技術股份有限公司（「復宏漢霖」，股票代碼：2696.HK）合作開發的重組抗血管內皮生長因子(Vascular endothelial growth factor, VEGF) more info >> |
|
|
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that a phase 1/2 clinical trial of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the Group and Shanghai Henlius Biotech, Inc. more info >> |
|
| Friday, April 14, 2023 |
|
|
亿胜生物与Osteopore签订口腔颌面产品在新加坡的独家代理协议 |
| 亿胜生物科技有限公司（“亿胜生物”或“集团”，股票代码：1061.HK）欣然宣布，集团全资附属子公司Majeton Pte. Ltd. ("Majeton")与Osteopore Limited ("Osteopore")达成合作，就Osteopore的牙科和口腔颌面产品("产品")签订独家代理协议。 more info >> |
|
|
億勝生物與Osteopore簽訂口腔頜面產品在新加坡的獨家代理協議 |
| 億勝生物科技有限公司（「億勝生物」或「集團」，股份代碼：1061.HK）欣然宣佈，集團全資附屬子公司Majeton Pte. Ltd. (「Majeton」)與Osteopore Limited (「Osteopore」)達成合作，就Osteopore的牙科和口腔頜面產品(「產品」)簽訂獨家代理協議。 more info >> |
|
|
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore |
| Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd. ("Majeton"), has entered into an exclusive Distribution Agreement with Osteopore Limited ("Osteopore") to promote and sell Osteopore's dental and oral maxillofacial products ("Products") in Singapore. more info >> |
|
| Tuesday, April 11, 2023 |
|
|
亿胜生物与郡是深圳签订皮耐克®可吸收性敷料在中国大陆的独家代理协议 |
| 亿胜生物科技有限公司（“亿胜生物”或“集团”，股份代码：1061.HK）欣然宣布，集团全资附属子公司珠海亿胜医药有限公司（“亿胜医药”）与日本郡是株式会社（“郡是”）全资子公司郡是医疗器材（深圳）有限公司（“郡是深圳”）达成合作 more info >> |
|
|
|
|
